Your institution may have access to this item. Find your institution then sign in to continue.
Title
Irinotecan plus gemcitabine and 5-fluorouracil in advanced pancreatic cancer: a phase II study.
Authors
Endlicher, E; Troppmann, M; Kullmann, A; Golder, S; Herold, T; Herfarth, H; Grossmann, J; Schlottmann, K; Kullmann, F
Abstract
The aim of the present study was to evaluate the 6-month survival rate of patients with inoperable or metastatic pancreatic cancer treated with irinotecan and gemcitabine plus 5-fluorouracil. Secondary efficacy end points included response rate, time to progression (TTP), overall survival (OS) and toxicity.